# Cancer Institute (WIA)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/cancer-institute-wia/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 67.8 |
| Citations | 2,120,442 |
| City | Chennai |
| Country | IN |
| Description | Cancer Institute (WIA) is a research organisation in Chennai, IN. OpenAlex records 18,577 works and 2,120,442 citations for it. 4,360 researchers list it as their most recent affiliation. |
| Homepage | http://cancerinstitutewia.in/CIWIA/ |
| OpenAlex ID | https://openalex.org/I2801345345 |
| Researchers | 4,360 |
| ROR ID | https://ror.org/01tc10z29 |
| Type | healthcare |
| Wikidata ID | https://www.wikidata.org/wiki/Q4686935 |
| Works | 18,577 |

## University collaborators

- [Emory University](https://scholariq.org/institutions/emory-university/)
- [Bristol-Myers Squibb (United States)](https://scholariq.org/institutions/bristol-myers-squibb-united-states/)

## University papers

Showing 12 of 40.

- [<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling](https://scholariq.org/papers/i-met-i-amplification-leads-to-gefitinib-resistance-in-lung-cancer-by-activating/)
- [Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-metastatic-nonsquamous-nsclc/)
- [First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer](https://scholariq.org/papers/first-line-crizotinib-versus-chemotherapy-in-i-alk-i-positive-lung-cancer/)
- [Interleukin-1 polymorphisms associated with increased risk of gastric cancer](https://scholariq.org/papers/interleukin-1-polymorphisms-associated-with-increased-risk-of-gastric-cancer/)
- [Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis](https://scholariq.org/papers/effects-of-kras-braf-nras-and-pik3ca-mutations-on-the-efficacy-of-cetuximab-plus/)
- [Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/breast-cancer-version-3-2020-nccn-clinical-practice-guidelines-in-oncology/)
- [Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial](https://scholariq.org/papers/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for/)
- [Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer](https://scholariq.org/papers/integrative-genome-analyses-identify-key-somatic-driver-mutations-of-small-cell/)
- [CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy](https://scholariq.org/papers/cd22-targeted-car-t-cells-induce-remission-in-b-all-that-is-naive-or-resistant/)
- [Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-docetaxel-versus-placebo-plus-docetaxel-for-second-line/)
- [Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/breast-cancer-version-3-2022-nccn-clinical-practice-guidelines-in-oncology/)
- [Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses](https://scholariq.org/papers/targeting-tumor-infiltrating-macrophages-decreases-tumor-initiating-cells/)

## University researchers

- [Staci Martin](https://scholariq.org/researchers/staci-martin/)

## University top topics

Showing 8 of 25.

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Advanced Radiotherapy Techniques](https://scholariq.org/topics/advanced-radiotherapy-techniques/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.